1228027-09-5

Upstream product

• 174293-33-5 (3aS,6aR)-2-benzylhexahydrocyclopenta[c]pyrrol-4(5H)-one 
• 1228029-77-3 racemic-(3aS*,4S*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ol 
• 1228029-78-4 (3aS,4S,6aR)-2-Benzyloctahydrocyclopenta[c]pyrrol-4-yl methanesulfonate 
• 1228029-79-5 (3aS,4R,6aR)-4-azido-2-benzyloctahydrocyclopenta[c]pyrrole 
• 1228027-34-6 tert-butyl methyl((S)-4-methyl-1-((3aS,4R,6aR)-octahydrocyclopenta[c]pyrrol-4-ylamino)-1-oxopentan-2-yl)carbamate 
• 2991-42-6 4-trifluorophenylsulfonyl chloride 
• 1228025-42-0 N₁-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N₂-(tert-butyloxycarbonyl)-N₂-methyl-L-leucinamide 
• 1228029-80-8 (3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine 

Downstream Products

• 1228025-68-0 N₂-methyl-N₁-((3aS,4R,6aR)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide 

Relevant academic research and scientific papers

Synthesis and SAR of 4-aminocyclopentapyrrolidines as orally active N-type calcium channel inhibitors for inflammatory and neuropathic pain

A novel series of N-type calcium channel inhibitors have been discovered. Optimization of potency and HT-ADME properties provides 4- aminocyclopentapyrrolidines with analgesic efficacy after oral dosing.

NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS

The present application relates to calcium channel inhibitors containing compounds of formula (I) wherein L1, L2, R1, R2, and R3 are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.